Speaker: Xavier Montalban

0:03:02

Xavier Montalban, EAN 2019 – Phase II study of first oral BTK inhibitor in multiple sclerosis

0:03:57

Xavier Montalban, EAN 2020 – Long-term Phase II Outcomes of First Oral BTK Inhibitor in MS

0:02:08

The diagnostic and therapeutic landscape of MS in 2021

0:00:50

Addressing unanswered questions in MS at AAN 2022

0:01:08

Neuroregenerative agents in progressive multiple sclerosis

0:37:01

2024 revised McDonald Criteria for Multiple Sclerosis

0:00:38

Assessing remibrutinib in patients with relapsing MS

2:08:45

5th Annual Congress of SLCTRIMS (2024) - Day 1 - Session 1

0:02:17

Future directions for progressive multiple sclerosis

0:01:20

Using digital technology to facilitate MS management

0:01:07

Prospective cohorts on CIS and treated patients with mutiple sclerosis

0:00:58

Future areas of improvement in treating MS

0:01:30

Differential efficacy of DMTs in patients with active and inactive MS

0:01:15

The safety and efficacy of evobrutinib in multiple sclerosis

0:03:14

Using DMTs beyond patients with active MS

0:58:43

PROMS Plenary Event 2023 - Session 01

0:04:46

Current treatments for primary and secondary progressive multiple sclerosis

0:01:10

Understanding the earliest stages of multiple sclerosis

0:01:59

Cognitive impairment associates with brain volume loss in multiple sclerosis

0:01:08

Assessing the interaction between blood NfL levels and BTK inhibitor efficacy in MS

0:02:04

Future avenues of MS treatment

0:01:53

The ECTRIMS 2022 Event for People with MS

0:01:34

Predicting treatment effect in MS patients: enrichment of certain baseline features in responders

0:29:25

Day 1 | 2nd Session: Highlights on Research in Progressive MS by Mar Tintoré